{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:19:22Z","timestamp":1791983962179,"version":"4.4.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61\/R33 NS119717"],"award-info":[{"award-number":["R61\/R33 NS119717"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ultra-rare Gene-based Therapy Network","award":["URGenT U01 NS132994"],"award-info":[{"award-number":["URGenT U01 NS132994"]}]},{"name":"Prion Alliance"},{"name":"Family Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prion protein (PrP) lowering is effective in animal models of prion disease and is being tested clinically in prion disease patients, but there remains a need for more potent PrP-lowering drug candidates. Inspired by the reported potency and duration of action of divalent short interfering RNA (siRNA), a new oligonucleotide drug modality for the central nervous system, we sought to discover and develop a new PrP-lowering drug candidate. Herein we identify a mouse Prnp-targeting divalent siRNA molecule, 1682-s4, that lowers PrP to 49% residual brain expression in wild-type mice, and, in the context of intracerebral infection with Rocky Mountain Laboratories prions, achieves a 2.7-fold increase in survival time with pre-symptomatic chronic treatment and 64% increase in survival time with a single dose after symptom onset. We describe the generation of two transgenic mouse lines, Tg25109 and Tg26372, expressing the full human\u00a0PRNP gene and its noncoding sequence, and demonstrate their utility for in vivo discovery of potent human PRNP-targeting oligonucleotides. We discover siRNA sequence 2439 against human PRNP and compare its potency in different divalent siRNA chemical scaffolds. We determine that both the fixed UU tail and extended nucleic acid linkages of scaffold s4 contribute to superior potency compared to other scaffolds tested, offering 9.4 and 15.9 percentage points respectively of additional PrP knockdown. A single dose of 348 \u00b5g of 2439-s4 lowered whole brain hemisphere human PrP in transgenic mice to 17% residual after 30 days, while 52 \u00b5g lowered PrP to 49% residual. A total of 1%\u20132% of the dose of 2439-s4 delivered into cerebrospinal fluid is retained in the brain, and the median effective tissue concentration is estimated at 1.2 \u03bcg per gram of tissue. Good Laboratory Practices toxicology studies identified no significant liabilities, and the US FDA has cleared an Investigational New Drug application to bring 2439-s4 into clinical trials.<\/jats:p>","DOI":"10.1093\/nar\/gkag287","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:42:21Z","timestamp":1773924141000},"source":"Crossref","is-referenced-by-count":17,"title":["Divalent siRNA for prion disease"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-4489","authenticated-orcid":false,"given":"Juliana E","family":"Gentile","sequence":"first","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4167-8291","authenticated-orcid":false,"given":"Taylor L","family":"Corridon","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7377-219X","authenticated-orcid":false,"given":"Fiona E","family":"Serack","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-0855","authenticated-orcid":false,"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary\u00a0C","family":"Kennedy","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie L","family":"Gallant-Behm","sequence":"additional","affiliation":[{"name":"Atalanta Therapeutics , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Hassler","sequence":"additional","affiliation":[{"name":"Atalanta Therapeutics , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth A","family":"Kinberger","sequence":"additional","affiliation":[{"name":"Atalanta Therapeutics , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret N","family":"Kelemen","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita G","family":"Kamath","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lian","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Y","family":"Gross","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Miller","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick","family":"DeSouza-Lenz","sequence":"additional","affiliation":[{"name":"Comparative Medicine, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Howard","sequence":"additional","affiliation":[{"name":"Comparative Medicine, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenia","family":"Guzman","sequence":"additional","affiliation":[{"name":"Comparative Medicine, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Chan","sequence":"additional","affiliation":[{"name":"Comparative Medicine, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Laversenne","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Curtis","sequence":"additional","affiliation":[{"name":"Atalanta Therapeutics , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Fettes","sequence":"additional","affiliation":[{"name":"FTS Pharma Consulting LLC , Medfield, MA 02052 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"ML Consult LLC , Cincinnati, OH 45220 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L","family":"Jackson","sequence":"additional","affiliation":[{"name":"Atalanta Therapeutics , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-8298","authenticated-orcid":false,"given":"Ken","family":"Yamada","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-0857","authenticated-orcid":false,"given":"Julia F","family":"Alterman","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-7793","authenticated-orcid":false,"given":"Alissa A","family":"Coffey","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-1608","authenticated-orcid":false,"given":"Eric Vallabh","family":"Minikel","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]},{"name":"McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]},{"name":"Department of Neurology, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Prion Alliance , Cambridge, MA 02139 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, UMass Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2702","authenticated-orcid":false,"given":"Sonia M","family":"Vallabh","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["United States"]},{"name":"McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]},{"name":"Department of Neurology, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Prion Alliance , Cambridge, MA 02139 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026042405072025700_B1","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026042405072025700_B2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","article-title":"Towards a treatment for genetic prion disease: trials and biomarkers","volume":"19","author":"Vallabh","year":"2020","journal-title":"Lancet Neurol"},{"key":"2026042405072025700_B3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/356577a0","article-title":"Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein","volume":"356","author":"B\u00fceler","year":"1992","journal-title":"Nature"},{"key":"2026042405072025700_B4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nbt1271","article-title":"Production of cattle lacking prion protein","volume":"25","author":"Richt","year":"2007","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mrd.20960","article-title":"Generation of goats lacking prion protein","volume":"76","author":"Yu","year":"2009","journal-title":"Mol Reprod Devel"},{"key":"2026042405072025700_B6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nn.2483","article-title":"Axonal prion protein is required for peripheral myelin maintenance","volume":"13","author":"Bremer","year":"2010","journal-title":"Nat Neurosci"},{"key":"2026042405072025700_B7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1297-9716-43-87","article-title":"Healthy goats naturally devoid of prion protein","volume":"43","author":"Benestad","year":"2012","journal-title":"Vet Res"},{"key":"2026042405072025700_B8","doi-asserted-by":"publisher","first-page":"322ra9","DOI":"10.1126\/scitranslmed.aad5169","article-title":"Quantifying prion disease penetrance using large population control cohorts","volume":"8","author":"Minikel","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026042405072025700_B9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2267-z","article-title":"Evaluating drug targets through human loss-of-function genetic variation","volume":"581","author":"Minikel","year":"2020","journal-title":"Nature"},{"key":"2026042405072025700_B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF03403528","article-title":"High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene","volume":"1","author":"B\u00fceler","year":"1994","journal-title":"Mol Med Camb Mass"},{"key":"2026042405072025700_B11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/0092-8674(93)90360-3","article-title":"Mice devoid of PrP are resistant to scrapie","volume":"73","author":"B\u00fceler","year":"1993","journal-title":"Cell"},{"key":"2026042405072025700_B12","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.1128\/jvi.69.12.7586-7592.1995","article-title":"Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent","volume":"69","author":"Sakaguchi","year":"1995","journal-title":"J Virol"},{"key":"2026042405072025700_B13","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/j.1460-2075.1996.tb00467.x","article-title":"Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie","volume":"15","author":"Fischer","year":"1996","journal-title":"EMBO J"},{"key":"2026042405072025700_B14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1090187","article-title":"Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis","volume":"302","author":"Mallucci","year":"2003","journal-title":"Science"},{"key":"2026042405072025700_B15","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1099\/vir.0.80947-0","article-title":"Prion clearance in bigenic mice","volume":"86","author":"Safar","year":"2005","journal-title":"J Gen Virol"},{"key":"2026042405072025700_B16","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1038\/mtna.2011.6","article-title":"Intracerebral infusion of antisense oligonucleotides into prion-infected mice","volume":"1","author":"Nazor\u00a0Friberg","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026042405072025700_B17","doi-asserted-by":"publisher","first-page":"e131175","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"5","author":"Raymond","year":"2019","journal-title":"JCI Insight"},{"key":"2026042405072025700_B18","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","author":"Minikel","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026042405072025700_B19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41591-024-03466-w","article-title":"In vivo base editing extends lifespan of a humanized mouse model of prion disease","volume":"31","author":"An","year":"2025","journal-title":"Nat Med"},{"key":"2026042405072025700_B20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostat Oxf Engl"},{"key":"2026042405072025700_B22","article-title":"Clinical development success rates and contributing factors 2011\u20132020","author":"Thomas","year":"2021"},{"key":"2026042405072025700_B23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nature"},{"key":"2026042405072025700_B24","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1038\/ncomms5347","article-title":"Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked","volume":"5","author":"Sandberg","year":"2014","journal-title":"Nat Commun"},{"key":"2026042405072025700_B25","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J Biol Chem"},{"key":"2026042405072025700_B26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026042405072025700_B27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: how do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"2026042405072025700_B28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B29","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/alz.13703","article-title":"Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer\u2019s disease","volume":"20","author":"Ferguson","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026042405072025700_B30","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/epi.18278","article-title":"Durable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNA","volume":"66","author":"Andreone","year":"2025","journal-title":"Epilepsia"},{"key":"2026042405072025700_B31","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1016\/j.ymthe.2025.05.010","article-title":"RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice","volume":"33","author":"Weiss","year":"2025","journal-title":"Mol Ther"},{"key":"2026042405072025700_B32","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026042405072025700_B33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41587-024-02336-7","article-title":"Enhancing siRNA efficacy in vivo with extended nucleic acid backbones","volume":"43","author":"Yamada","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.molcel.2013.04.001","article-title":"Highly complementary target RNAs promote release of guide RNAs from human Argonaute2","volume":"50","author":"De","year":"2013","journal-title":"Mol Cell"},{"key":"2026042405072025700_B36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.molcel.2019.06.019","article-title":"Structural basis for target-directed MicroRNA degradation","volume":"75","author":"Sheu-Gruttadauria","year":"2019","journal-title":"Mol Cell"},{"key":"2026042405072025700_B37","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"key":"2026042405072025700_B38","doi-asserted-by":"publisher","first-page":"10905","DOI":"10.1093\/nar\/gky745","article-title":"Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs","volume":"46","author":"Shmushkovich","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2026042405072025700_B39","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1074\/jbc.M116.773283","article-title":"Modifiers of prion protein biogenesis and recycling identified by a highly parallel endocytosis kinetics assay","volume":"292","author":"Ballmer","year":"2017","journal-title":"J Biol Chem"},{"key":"2026042405072025700_B40","doi-asserted-by":"publisher","first-page":"107560","DOI":"10.1016\/j.jbc.2024.107560","article-title":"Modulation of prion protein expression through cryptic splice site manipulation","volume":"300","author":"Gentile","year":"2024","journal-title":"J Biol Chem"},{"key":"2026042405072025700_B41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"key":"2026042405072025700_B42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1084\/jem.20151610","article-title":"Strictly co-isogenic C57BL\/6J-Prnp-\/- mice: a rigorous resource for prion science","volume":"213","author":"Nuvolone","year":"2016","journal-title":"J Exp Med"},{"key":"2026042405072025700_B43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/nbt.2959","article-title":"Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping","volume":"32","author":"de\u00a0Vree","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-020-01608-8","article-title":"Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease","volume":"18","author":"Vallabh","year":"2020","journal-title":"BMC Med"},{"key":"2026042405072025700_B45","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.omtn.2024.102359","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation","volume":"35","author":"Miller","year":"2024","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"2026042405072025700_B46","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1016\/j.ymthe.2024.10.024","article-title":"Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system","volume":"32","author":"Moazami","year":"2024","journal-title":"Mol Ther"},{"key":"2026042405072025700_B47","doi-asserted-by":"publisher","first-page":"gkag057","DOI":"10.1093\/nar\/gkag057","article-title":"Transient acute neuronal activation response caused by high concentrations of oligonucleotides in the cerebral spinal fluid","volume":"54","author":"Hernandez","year":"2026","journal-title":"Nucleic Acids Res"},{"key":"2026042405072025700_B48","article-title":"Avertin solution for mouse anesthesia","author":"Jones"},{"key":"2026042405072025700_B49","doi-asserted-by":"publisher","article-title":"PrP turnover in vivo and the time to effect of prion disease therapeutics","author":"Corridon","DOI":"10.1101\/2024.11.12.623215"},{"key":"2026042405072025700_B50","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(61)92008-6","article-title":"Encephalopathy in mice produced by inoculation with scrapie brain material","volume":"277","author":"Chandler","year":"1961","journal-title":"Lancet"},{"key":"2026042405072025700_B51","doi-asserted-by":"publisher","first-page":"e156532","DOI":"10.1172\/jci.insight.156532","article-title":"Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS","volume":"7","author":"Mortberg","year":"2022","journal-title":"JCI Insight"},{"key":"2026042405072025700_B52","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1074\/jbc.RA120.014905","article-title":"Multimodal small-molecule screening for human prion protein binders","volume":"295","author":"Reidenbach","year":"2020","journal-title":"J Biol Chem"},{"key":"2026042405072025700_B53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/nat.2017.0690","article-title":"Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay","volume":"27","author":"Godinho","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"2026042405072025700_B54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/17425255.2023.2283524","article-title":"Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK\/PD modelling","volume":"19","author":"Gao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026042405072025700_B55","article-title":"Oligonucleotides for prnp modulation","author":"Khvorova","year":"2021"},{"key":"2026042405072025700_B56","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nbt.1644","article-title":"A mouse knockout library for secreted and transmembrane proteins","volume":"28","author":"Tang","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026042405072025700_B57","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature19356","article-title":"High-throughput discovery of novel developmental phenotypes","volume":"537","author":"Dickinson","year":"2016","journal-title":"Nature"},{"key":"2026042405072025700_B58","article-title":"Frmd6 | FERM domain containing 6 mouse gene | IMPC","journal-title":"Int Mouse Phenotyping Consort IMPC"},{"key":"2026042405072025700_B59","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1126\/science.1258040","article-title":"Structural basis for microRNA targeting","volume":"346","author":"Schirle","year":"2014","journal-title":"Science"},{"key":"2026042405072025700_B60","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.molcel.2019.06.012","article-title":"High-throughput analysis reveals rules for target RNA binding and cleavage by AGO2","volume":"75","author":"Becker","year":"2019","journal-title":"Mol Cell"},{"key":"2026042405072025700_B61","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.molcel.2024.06.026","article-title":"The guide-RNA sequence dictates the slicing kinetics and conformational dynamics of the Argonaute silencing complex","volume":"84","author":"Wang","year":"2024","journal-title":"Mol Cell"},{"key":"2026042405072025700_B62","article-title":"Compounds and methods for reducing prion expression","author":"Freier","year":"2020"},{"key":"2026042405072025700_B63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1091581817741840","article-title":"Toxicology evaluation of drugs administered via uncommon routes: intranasal, intraocular, intrathecal\/intraspinal, and intra-articular","volume":"37","author":"Emami","year":"2018","journal-title":"Int J Toxicol"},{"key":"2026042405072025700_B64","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1089\/nat.2024.0036","article-title":"An evaluation of first-in-human studies for RNA oligonucleotides","volume":"34","author":"Stern","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"2026042405072025700_B65","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042405072025700_B66","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-Nejad","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2026042405072025700_B67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/21593337251371594","article-title":"Cell type distribution of intrathecal antisense oligonucleotide activity in deep brain regions of non-human primates","volume":"35","author":"Frei","year":"2025","journal-title":"Nucleic Acid Ther"},{"key":"2026042405072025700_B68","volume-title":"Widespread and Durable Knockdown of HTT in Non-Human Primate Brain by a Novel Oligonucleotide Modality","author":"McDonough"},{"key":"2026042405072025700_B69","doi-asserted-by":"publisher","first-page":"e152203","DOI":"10.1172\/jci.insight.152203","article-title":"Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep","volume":"6","author":"Ferguson","year":"2021","journal-title":"JCI Insight"},{"key":"2026042405072025700_B70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1056\/NEJMc2000687","article-title":"Variant creutzfeldt-jakob disease diagnosed 7.5 years after occupational exposure","volume":"383","author":"Brandel","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042405072025700_B71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.373.6554.475","article-title":"France halts prion research amid safety concerns","volume":"373","author":"Casassus","year":"2021","journal-title":"Science"},{"key":"2026042405072025700_B72","doi-asserted-by":"publisher","article-title":"Zinc finger repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice","author":"Chou","DOI":"10.1101\/2025.03.05.636713"},{"key":"2026042405072025700_B73","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1126\/science.adp3043","article-title":"Foiling deadly prions","volume":"383","author":"Wadman","year":"2024","journal-title":"Science"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/8\/gkag287\/68146557\/gkag287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/8\/gkag287\/68146557\/gkag287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:07:29Z","timestamp":1777021649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkag287\/8661641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,23]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkag287","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,8]]},"published":{"date-parts":[[2026,4,23]]},"article-number":"gkag287"}}